Answers are grounded in this paper and cite their sources.
Autoimmune and autoinflammatory diseases are a diverse group of disorders that stem from aberrant immune responses against self. While autoimmune disorders are characterized by lymphocyte driven antigen-specific responses, autoinflammatory diseases are driven by chronic activation of the innate immune system. However, to date, both groups of disorders lack clear understanding for their onset, the functional mechanisms conducive to their pathology, and have few efficacious, safe, and/or curative treatment options for patients. The SH2 domain-containing protein tyrosine phosphatase (SHP2), the protein encoded by the PTPN11 gene, is a nodal enzyme involved in embryogenesis, development, proliferation, differentiation, and survival of cells. Mutations in PTPN11 are associated with the development of congenital disorders as well as several types of cancers. Recently, links between autoimmunity and genetic developmental disorders have also revealed a key role for SHP2 activity in autoimmune autoinflammatory pathophysiology. Its association with these disorders has begun to unravel the molecular mechanisms that contribute to the onset of autoimmunity. In this review, we will discuss the emergent role for SHP2 in autoimmunity, the current known and unknown molecular mechanisms of its regulation in these processes and propose the translational impact it may have as a therapeutic in the near future.
No takes yet. Share an insight, caveat, or question.
Sommer et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: